PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (NCT05407584) | Yonsei University | 2022-07-05 |
Track PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment automatically
Every clearance here is in the API, with alerts when new ones post.